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A 78-year-old woman receiving treatment for limited systemic scleroderma (SSc) underwent high anterior resection
and partial liver resections for rectosigmoid colon cancer with multiple liver metastases. A year after surgery, an
abdominal computed tomography (CT) demonstrated suspicion for peritoneal dissemination with an increase in
ascites, and 18F-fluorodeoxy glucose-positron emission tomography-CT was suggestive of carcinomatosis. We began
to decompress the small intestine and administer octreotide. However, the intestinal obstruction did not improve.
Although intestinal pseudo-obstruction caused by limited SSc was considered as a differential diagnosis, we
performed an exploratory laparotomy because the possibility of peritoneal dissemination-associated obstruction
could not be excluded. We observed a moderate amount of serous ascites and dilatation of the small intestine that
was white in color, hard, and with limited contractility. There was no evidence of peritoneal dissemination nor of
mechanical obstruction. Our experience thus shows the difficulty of distinguishing SSc-associated intestinal pseudo-
obstruction from peritoneal dissemination.
Keywords: Pseudo-obstruction; Peritoneal recurrence; Limited systemic scleroderma; FDG PET-CTBackground
Intestinal pseudo-obstruction is caused by several dis-
eases including connective tissue disorders,
hypothyroidism, Chagas’ disease, diabetes, and Parkin-
son’s disease. Systemic scleroderma (SSc) is a chronic
disorder of the connective tissue characterized by in-
flammation, fibrosis, and degeneration of the skin and
blood vessels and is known to cause intestinal pseudo-
obstruction [1-5]. The radiographic findings of intestinal
pseudo-obstruction caused by SSc are a hide-bound
bowel sign or accordion sign on abdominal X-ray or
contrast study and pneumatosis cystoides intestinalis on
abdominal computed tomography (CT) [3,6-8]. How-
ever, these findings cannot exclude mechanical obstruc-
tion such as that caused by postoperative adhesions or
peritoneal dissemination. Although 18F-fluorodeoxy* Correspondence: saigusa@wakabahsp.jp
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is a useful tool to detect peritoneal metastases, low-
grade FDG uptake should be carefully assessed because
it is difficult to differentiate inflammation or fibrotic
change from tumor recurrence [9-12]. We report a case
in which it was difficult to distinguish between SSc-
associated pseudo-obstruction and peritoneal dissemin-
ation in a SSc patient after surgery for stage IV colon
cancer.Case presentation
A 78-year-old woman receiving treatments including the
administration of low dose of corticosteroid and proton
pump inhibitor for LSSc (antinuclear antibody: positive;
anti-centromere antibody: positive; anti-topoisomerase
antibody: negative; anti-ribonucleoprotein antibody:
negative) for 7 years underwent high anterior resection
and partial liver resections for rectosigmoid colon cancer
with multiple liver metastases (S4, S6, and S8). The pre-
operative serum levels of carcinoembryonic antigen
(CEA) and carbohydrate antigen (CA19-9) were 7.9 ng/an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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range, 0 to 37.0 U/ml). Pathological findings showed
well-differentiated tubular adenocarcinoma, T3N1M1
with lymphatic invasion. On partial resection for each
liver metastasis, S4 lesion resulted in positive resection
margin. Although she received adjuvant therapy (cape-
citabine plus oxaliplatin) for 6 months after surgery, she
stopped the therapy because of the side effects. A year
after the surgery, an abdominal CT demonstrated sus-
pected peritoneal dissemination with increased ascites
(Figure 1A). Tumor markers were not increased (both
CEA and CA19-9 were within normal range), but the as-
cites was increasing and obstructive symptoms such as
nausea, emesis, and abdominal distension worsened.
Contrast study showed delayed transit through the small
intestine with eventual movement into the colon. To
confirm whether or not there was any evidence of tumor
recurrence, we performed FDG PET-CT, which sug-
gested peritonitis carcinomatosa with diffuse low-grade
FDG uptake along the small intestinal wall (Figure 1B).
We began to decompress the small intestine and admin-
ister octreotide. However, the intestinal dilatation and
stasis did not improve (Figure 2). Although pseudo-
obstruction caused by LSSc was considered as a differen-
tial diagnosis, we performed an exploratory laparotomy
because the possibility of partial obstruction caused by
peritoneal dissemination could not be excluded and the
patient failed to improve with conservative measures.
Preoperative laboratory investigation revealed anemia
(hemoglobin 9.6 g/dl), mild elevated liver enzymes (as-
pirate aminotransferase 43 IU/l, alanine aminotransfer-
ase 47 IU/l), and poor nutritional condition (total
protein 4.9 g/dl, albumin 2.9 g/dl).Upon laparotomy, weA
B
Figure 1 Increase in ascites and diffuse low-grade FDG uptake. Abdom
intestinal wall (A). Diffuse low-grade FDG uptake along the small intestinalobserved a moderate amount of serous ascites and dila-
tation of the small intestine overlying which was a whit-
ish film. The bowel was hardened, with wall thickness
and limited contractility, similar to findings in encapsu-
lating peritoneal sclerosis (Figure 3A,B). Its findings
were observed in all the small intestine. However, there
was no evidence of peritoneal dissemination or mechan-
ical obstruction. Eventually, we performed an enteros-
tomy and sampling of the small intestinal serosa. On
histopathological examination, fibrotic change in the
muscle and serosal layers was observed (Figure 3C).
Postoperatively, we administrated neostigmine bromide
as a substitute for octreotide (not approved for this indi-
cation in Japan) and erythromycin to promote intestinal
motility, but these treatments were not effective. We
treated her with the decompression of the small intes-
tine via enterostomy for stasis and total parenteral nutri-
tion for stasis-related malabsorption and malnutrition.
However, her general condition such as anasarca in-
duced by malnutrition was gradually worse. Ultimately,
she suffered from sepsis caused by stasis-related bacter-
ial overgrowth and translocation, and died on postopera-
tive day 77.
Conclusions
Gastrointestinal involvement is the most common non-
dermatologic complication in patients with SSc [3,13].
Gastrointestinal dysfunction can severely and negatively
impact quality of life and is associated with a poor prog-
nosis [14-18]. Limited SSc is a subtype of systemic
scleroderma that was previously referred to as CREST
syndrome (calcinosis, Raynaud’s phenomenon, esopha-
geal dysmotility, sclerodactyly, telangiectasias). Patientsinal CT shows an increase in ascites and mild thickness of the small
wall (white arrows) (B).
BA
Figure 2 Abdominal X-ray before surgery. Upright position (A), supine position (B).
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their elbows, knees, and face and are more likely to de-
velop pulmonary hypertension. Patients with another
subtype of SSc, diffuse SSc, develop not only distal but
also proximal sclerosis and tend to have more significant
visceral organ involvement than those with limited SSc.
However, gastrointestinal involvement is common in
both subtypes and the severity of cutaneous and gastro-
intestinal manifestations often does not correlate
[3,19,20]. Pathologic manifestations in patients with SSc
are due to progressive fibrosis of intestinal smooth
muscle. Physiologically, inflammation of the myenteric
ganglia and fibrosis of gastrointestinal muscle have been
found in patients with SSc [21,22]. Small intestinalA
Figure 3 Operative and histopathological findings. Dilatation and hard
small intestine (B). Fibrotic change in the muscle and serosal layers (C). Hehypomotility causes luminal dilatation and stasis of lu-
minal contents resulting in a pseudo-obstruction, lead-
ing to stasis-related malabsorption. Secondary small
intestinal bacterial outgrowth affects almost half of pa-
tients with SSc [5,23-25]. It has been reported that
octreotide is the most potent prokinetic drug for
pseudo-obstruction [26,27]. However, octreotide did not
improve motility in the present case. Moreover, erythro-
mycin, which mimics motilin, known as the prokinetic
hormone, was also not effective, despite the fact that
several authors have reported upon its effectiveness for
pseudo-obstruction [28,29]. We think that the lack of ef-
fectiveness of these drugs is due to the progressive fibro-
sis of the small intestine and malabsorption by smallB
C
ening of the small intestine (A). Diffuse fibrotic change throughout the
matoxylin and eosin stain, original magnification × 40.
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teral nutrition in the form of an elemental diet via the
enterostomy with concomitant administration of antibi-
otics such as metronidazole [30,31], the nutrition status
of our patient did not improve. We think that early diag-
nosis and treatment for pseudo-obstruction is important,
along with the collaboration of rheumatologists and gas-
troenterologists in patients with gastrointestinal involve-
ment of SSc. Although we lack a complete
understanding of the progressive nature of the disease,
the presence of carcinoma in addition to adjuvant
chemotherapy may compound the situation [32].
On radiographic examination, abdominal X-ray did not
show the typical appearance of SSc-associated pseudo-
obstruction such as the hide-bound bowel sign [3,6-8]. Al-
though we observed pneumatosis cystoides intestinalis in
the descending colon 2 months before exploratory laparot-
omy, this finding was not noted during the surgery. Given
the increase in ascites and occurrence of obstructive
symptoms, most would suspect peritoneal recurrence in a
patient with stage IV colon cancer after surgery. FDG
PET-CT has the potential to improve detection of periton-
eal carcinomatosa [9-12]. However, FDG uptake is also
present in cases of fibrosis and inflammation, and it is dif-
ficult to distinguish this pathology from peritoneal metas-
tasis [9-12]. Although diffuse low-grade FDG uptake (up
to the maximum standardized uptake value of 2.3) along
the small intestinal wall was observed, we were unable to
definitively diagnose the current case as one of intestinal
pseudo-obstruction. Several authors reported that evalu-
ation for radiation-induced fibrosis and retroperitoneal fi-
brosis is helpful [33-35]. On the other hand, Nishiyama
et al. have reported that FDG PET-CT is useful to evaluate
the degree of disease associated with connective tissue dis-
order [36]. In the current case, we think that elevated
FDG uptake along the small intestinal wall was indicative
of inflammation and fibrosis.
In conclusion, our experience suggests that it is diffi-
cult to distinguish LSSc-associated intestinal pseudo-
obstruction from peritoneal dissemination. Although
FDG PET-CT is an effective tool for detection of peri-
toneal metastasis, comprehensive assessment of the find-
ings in a patient with both SSc and advanced
gastrointestinal cancer is necessary.
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